Gestational malaria in Kisangani: Efficacy of Mefloquine versus Sulfadoxine-Pyrimethamine in Intermittent Preventive Treatment

Not Applicable

• Conditions: Pregnancy and Childbirth; Malaria

• Registration Number: PACTR201905899965726
• Lead Sponsor: niversity of Kisangani

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-05-08
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Pending
• Sex: Female
• Target Recruitment: 300

Inclusion Criteria

Pregnant women who will :
- begin antenatal visits in medical facilities selected from gestational age between 16 and 18 weeks of amenorrhea,
- have not yet received SP prophylaxis during ongoing pregnancy
- sign their consent form.

Exclusion Criteria

Pregnant women with :
- positive HIV serology,
- story of morbid neurological and psychiatric,
- story of SP allergy
- of antimalarial drug(s) use within 15 days prior to selection will be excluded.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
- Mefloquine will be well tolerated by Kisangani pregnant women;<br>- Mefloquine will be more effective than SP in pregnant women in Kisangani.<br>

Secondary Outcome Measures

Name	Time	Method
- Mefloquine Side-effects will be less frequent and minors, easy to control;<br>- The prevalence of maternal anemia at delivery will be lower among pregnant women who have taken the Mefloquine compared to those who will use Sulfadoxine-Pyrimethamine;<br>- Placental malaria parasitemia will be lower among pregnant women who have taken the Mefloquine compared to those who will use Sulfadoxine-Pyrimethamine;<br>- The prevalence of low birth will be lower among pregnant women who have taken the Mefloquine compared to those who will use Sulfadoxine-Pyrimethamine.